Paphos General Hospital is the Paphos district's main medical centre. With four stories and 25,000 square metres (270,000 sq ft) this pyramid shaped hospital is designed to offer to patients first aid to MRI Scans. When opened in 1992 it was considered one of the best medical centers in the Middle East.[citation needed] Nowadays this is not valid. The hospital was left to decline and it is currently unable to handle the rapidly growing population of Paphos. For minor expanding needs a few of the several atriums were transformed to interior spaces, but currently everybody is talking for an emergency expansion into land next to the facilities owned by the hospital.The hospital operates all the necessary departments. Within there is also a 200 seat auditorium, and there is a heliport right next to the emergency department.
Introduction: Propylthiouracil (PTU) is typically used as first line therapy for hyperthyroidism but is associated with a spectrum of adverse effects including vasculitis, that may lead to acute renal failure and exceptionally to pancreatitis, represents the most severe. Case description: Here we present the case of a 43-year-old woman with a history of Graves’ disease until recently on PTU therapy, who presented with fever and myalgia complicated by cold agglutinin disease, acute renal failure and pancreatitis. Subsequent laboratory studies and thorough physical examination excluding other causes revealed the presence of antibodies against leukocyte proteinase 3. Prompt initiation of immunosuppressive therapy and plasmapheresis led to immediate improvement of the patient’s clinical condition and laboratory tests. Conclusion: Clinicians should maintain a high index of suspicion for autoimmune phenomena in patients receiving PTU even after cessation of the medication. Early recognition, immediate discontinuation of the drug, and timely initiation of immunosuppressive therapy are essential to prevent irreversible organ damage.
The assessment of left and right ventricular systolic function is vital information for the management of cardiac disease. Everyday clinical practice has traditionally relied on the measurement of the ejection fraction (EF). Nonetheless, EF has known limitations and may not always accurately reflect myocardial systolic performance. Intrinsic myocardial contractility may decline long before reductions in left or right ventricular EF become apparent. Adjunct parameters such as tissue Doppler-derived systolic velocities of the mitral and tricuspid annulus may detect such early abnormalities; however, they do not represent global systolic performance. Consequently, commonly used indices may exhibit suboptimal performance for the detection of systolic dysfunction. Given the limitations of current measurement methods, there is growing concern about the reliability of heart failure (HF) classification based solely on EF. The integration of advanced echocardiographic indices, such as speckle-tracking-derived strain, three-dimensional (3D) volumetric assessment, myocardial work (MW), and cardiac power output (CPO), in combination with classical parameters provides more accurate, reproducible, and clinically meaningful diagnostic and prognostic information in patients with HF. Nevertheless, despite their potential, these techniques remain underutilized in routine practice. Early identification of systolic dysfunction and timely initiation of therapy can substantially improve clinical outcomes. In this setting, this review aims to comprehensively examine both established and emerging echocardiographic techniques used for the assessment of ventricular systolic performance, with the objective of promoting their effective integration into routine clinical practice.
Human echinococcosis (hydatidosis or hydatid) disease is a worldwide neglected zoonotic larval infection typically caused by cestodes of the Echinococcus genus. It affects 1 million people worldwide, predominantly reported in Central Asia, the Middle East, and South America. In this paper, we report a patient who underwent a successful laparoscopic partial pericystectomy and omentoplasty with simultaneous cholecystectomy in the treatment of cystic echinococcosis and cholelithiasis, respectively. There are many challenges to treating complicated hepatic hydatid cysts. It is crucial for surgeons to have knowledge of the range of possibilities of each surgical modality and its expanding advancements that can reduce complication risks and increase a patient’s quality of life. The art of sharing techniques and management possibilities between professionals in this field provides a bridge in further crafting the best-tailored treatment plan for patients. This report illustrates the successful usage of laparoscopy in the management of a section IV hydatid cyst with simultaneous cholecystectomy. This case aims to expand the knowledge and prospects of laparoscopic surgery in cystic echinococcosis.
PVR (CD155) and CD112 are ligands from the Nectin/Nectin-like family, frequently expressed on various tumor cells. PVR binds to the inhibitory receptors TIGIT and CD96, triggering a direct inhibitory signal in T and NK cells, and binds to the co-stimulatory receptor DNAM1 (CD226), leading to its downregulation. CD112 binds to the inhibitory receptor PVRIG and to DNAM1, stimulating T and NK cells. Late-stage clinical trials of anti-TIGIT monoclonal antibodies (mAbs) have shown mixed results regarding efficacy (Cho et al. Lancet Oncol. 2022 Jun;23(6):781-792; Rudin et al. J Clin Oncol. 2024 Jan 20;42(3):324-335). Numerous anti-PVR, anti-CD96, and anti-PVRIG mAbs, along with their combinations with anti-TIGIT mAbs and other therapies, are currently in early clinical development. This study aimed to compare how the complete inhibition of TIGIT, PVRIG, PVR, or their combinations affects the engagement of TIGIT, CD96, PVRIG, and DNAM1. We developed a mechanistic model describing the surface expression of PVR and CD112 on cancer cells, and TIGIT, CD96, DNAM1, and PVRIG on CD8 T-cells. This model captures the interactions of these ligands and receptors within the immunological synapse (IS) between CD8 T-cells and cancer cells in the tumor. In vitro data and expression data of these ligands and receptors were used to identify parameters. The model was validated against data on the downmodulation of DNAM1 and TIGIT on CD8 T-cells in the tumor compared to the blood. We simulated total DNAM1 on the surface of CD8 T-cells in the tumor and the engagement of TIGIT, CD96, PVRIG, and DNAM1 in the IS (i.e., the number of PVR:TIGIT, PVR:CD96, CD112:PVRIG, PVR:DNAM1, and CD112:DNAM1 complexes) under 100% inhibition of TIGIT, PVR, PVRIG, TIGIT and PVRIG, or PVR and PVRIG. TIGIT blockade did not increase DNAM1 engagement. Moreover, 100% inhibition of TIGIT led to the release of additional free PVR, resulting in the downmodulation of total DNAM1 and an increase in CD96 engagement. Inhibition of PVRIG resulted in an approximately 1.3-fold increase in bound DNAM1, but not in total DNAM1. The combination of TIGIT and PVRIG blockade did not increase engaged DNAM1 beyond the levels observed with anti-PVRIG monotherapy. Inhibition of PVR led to a significant increase in total DNAM1 and a moderate increase in bound DNAM1 (approximately 1.3-fold), along with the disruption of TIGIT and CD96 engagements. The combination of PVR and PVRIG blockade resulted in the strongest increase in engaged DNAM1 (approximately 2-fold), in addition to disrupting TIGIT, CD96, and PVRIG engagements. The inability to increase DNAM1 engagement during TIGIT inhibition may be one of the reasons for the lack of efficacy observed in the phase 3 trial of tiragolumab (anti-TIGIT mAb) used in combination with atezolizumab. Targeting PVR alone or in combination with PVRIG appears to be a better strategy than targeting TIGIT or TIGIT in combination with PVRIG. Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov. Assessing strategies to activate DNAM1 signaling and inhibit the TIGIT/PVRIG axis using mathematical modeling. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3219.
Tarlatamab is a DLL3/CD3 bispecific T-cell engager (TCE) recently approved by the FDA for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The dosing follows a step-up regimen for the first cycle, with 1 mg given on day 1, and 10 mg given on days 8 and 15. A similar step-up dosing regimen, but with 100 mg instead of 10 mg, was also tested in a pivotal phase 2 trial (Ahn et al. N Engl J Med. 2023 Nov 30;389(22):2063-2075). The alternative step-up dose or step-up regimen were not investigated in the study. The aim of our work was to explore the alternative step-up regimens of tarlatamab, predicting trimer (complex of TCE with target receptors) kinetics in the tumor using quantitative systems pharmacology (QSP) modeling. The QSP model integrated pharmacokinetics of tarlatamab, its distribution into the tumor of patients with ES-SCLC, binding with CD3 expressed by T-cells and DLL3 expressed by cancer cells, formation of trimer in the immunological synapse between T-cell and cancer cell, turnover of free and bound receptors, trimer internalization. Predicted peak trimer levels in the tumor are associated with cytokine release syndrome (CRS) incidence following tarlatamab administration. Higher peak levels of trimer are predicted for the doses and regimens causing more frequent CRS events. The model showed that 1 mg is the optimal step-up dose for the regimens tested in clinical trials since lower doses led to a higher peak trimer level after second dose (10 mg given on day 8). However, split dosing of the 1st or 2nd doses and a longer step-up schedule decreased the peak trimer levels following tarlatamab administration. Splitting the first dose in the approved regimen resulted in a reduction of peak trimer by 30-40%, thus mitigating CRS incidence. Administration of the 0.5 mg on day 1 and 0.5 mg on day 4 also caused a minor decrease of peak trimer level after administration of 10 mg on day 8. A substantial reduction of the maximal level of the trimer after the second dose was predicted for the step-up regimen with 100 mg if the second dose given on day 8 is 3 mg instead of 100 mg. This dose optimization might lower the probability of CRS grade 3 events observed in patients treated with 100 mg. Split-dose regimens and regimens with more than one step-up dose allow for minimizing CRS incidence without compromising the efficacy of TCEs. QSP modeling is a useful tool to investigate various doses and regimens of bispecific and multispecific antibodies. Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov. Optimization of tarlatamab step-up dosing regimen to mitigate cytokine release syndrome using quantitative systems pharmacology modeling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2130.